{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:50:54Z","timestamp":1775872254903,"version":"3.50.1"},"reference-count":29,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer immunotherapies have a class of medications called checkpoint inhibitors that can induce endocrinopathies including hypothyroidism, hypophysitis, and adrenalitis. This case illustrates a 72-year-old woman with recently diagnosed non-small cell lung cancer (NSCLC) who developed immune-mediated hypothyroidism and subsequent type 1 diabetes mellitus (T1DM) presenting as diabetic ketoacidosis (DKA) after 3 months of combination immunotherapy with nivolumab and ipilimumab. After her hospitalization, she was discharged on insulin. Our clinical case not only provides more literature on the risks involved with immunotherapy but also shows a rare outcome with checkpoint inhibitor\u2013induced T1DM.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag041","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:54:04Z","timestamp":1773824044000},"source":"Crossref","is-referenced-by-count":1,"title":["Combined immune checkpoint inhibitor\u2013induced type 1 diabetes: a rare but serious endocrinopathy"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5299-6866","authenticated-orcid":false,"given":"Kasra","family":"Emami","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mary Washington Healthcare , Fredericksburg, VA 22401 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mary Washington Healthcare , Fredericksburg, VA 22401 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Akula","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mary Washington Healthcare , Fredericksburg, VA 22401 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Amoakohene","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mary Washington Healthcare , Fredericksburg, VA 22401 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026031804535524800_luag041-B1","doi-asserted-by":"crossref","first-page":"1010279","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026031804535524800_luag041-B2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2026031804535524800_luag041-B3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12902-019-0467-z","article-title":"Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports","volume":"19","author":"Zezza","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"2026031804535524800_luag041-B4","doi-asserted-by":"crossref","first-page":"101657","DOI":"10.1016\/j.beem.2022.101657","article-title":"Type 1 diabetes related to immune checkpoint inhibitors","volume":"36","author":"Tachibana","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2026031804535524800_luag041-B5","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026031804535524800_luag041-B6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"issue":"3","key":"2026031804535524800_luag041-B7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center","volume":"6","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2026031804535524800_luag041-B8","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T-lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"10","key":"2026031804535524800_luag041-B9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"5","key":"2026031804535524800_luag041-B10","doi-asserted-by":"crossref","first-page":"e27077","DOI":"10.1016\/j.heliyon.2024.e27077","article-title":"Thyroid dysfunction (TD) induced by PD-1\/PD-L1 inhibitors in advanced lung cancer","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"2026031804535524800_luag041-B11","doi-asserted-by":"crossref","first-page":"885001","DOI":"10.3389\/fpubh.2022.885001","article-title":"PD-1 inhibitor-associated type 1 diabetes: a case report and systematic review","volume":"10","author":"Lin","year":"2022","journal-title":"Front Public Health"},{"issue":"6","key":"2026031804535524800_luag041-B12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.eprac.2020.12.009","article-title":"Real-world evidence of the incidence of and risk factors for type 1 diabetes mellitus and hypothyroidism as immune-related adverse events associated with programmed cell death-1 inhibitors","volume":"27","author":"Shimada","year":"2021","journal-title":"Endocr Pract"},{"issue":"5","key":"2026031804535524800_luag041-B13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc21-2213","article-title":"Immune checkpoint inhibitors and risk of type 1 diabetes","volume":"45","author":"Chen","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"2026031804535524800_luag041-B14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026031804535524800_luag041-B15","doi-asserted-by":"crossref","first-page":"1448728","DOI":"10.3389\/fimmu.2024.1448728","article-title":"A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"2026031804535524800_luag041-B16","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"2026031804535524800_luag041-B17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/cancers14010089","article-title":"CANDIED: a pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus","volume":"14","author":"Muniz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026031804535524800_luag041-B18","first-page":"e70058","article-title":"Immunotherapy-induced type 1 diabetes mellitus causing diabetic ketoacidosis: a case report and review of current guidelines","volume":"7","author":"Disterhaft","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"issue":"9","key":"2026031804535524800_luag041-B19","first-page":"e10632","article-title":"Diabetic ketoacidosis: an adverse reaction to immunotherapy","volume":"12","author":"Keerty","year":"2020","journal-title":"Cureus"},{"key":"2026031804535524800_luag041-B20","doi-asserted-by":"crossref","first-page":"154870","DOI":"10.1016\/j.metabol.2021.154870","article-title":"The \u03b2-cell glucose toxicity hypothesis: attractive but difficult to prove","volume":"124","author":"Weir","year":"2021","journal-title":"Metabolism"},{"issue":"12","key":"2026031804535524800_luag041-B21","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"64","author":"Holt","year":"2021","journal-title":"Diabetologia"},{"issue":"3","key":"2026031804535524800_luag041-B22","first-page":"e242","article-title":"Development of type 1 diabetes after cancer immunotherapy","volume":"3","author":"Hao","year":"2017","journal-title":"AACE Clin Case Rep"},{"issue":"6","key":"2026031804535524800_luag041-B23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab J"},{"issue":"11","key":"2026031804535524800_luag041-B24","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor\u2013associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026031804535524800_luag041-B25","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.3390\/ijms241210012","article-title":"Anti-islet autoantibodies in type 1 diabetes","volume":"24","author":"Kawasaki","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026031804535524800_luag041-B26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of immune checkpoint inhibitor-induced diabetes","volume":"10","author":"Ruiz-Esteves","year":"2024","journal-title":"JAMA Oncol"},{"issue":"12","key":"2026031804535524800_luag041-B27","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.2337\/dc20-0609","article-title":"Immune checkpoint inhibitor-associated diabetes: a single-institution experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"issue":"3","key":"2026031804535524800_luag041-B28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1573399814666180730105351","article-title":"Type 1 diabetes-related autoantibodies in different forms of diabetes","volume":"15","author":"S\u00f8rgjerd","year":"2019","journal-title":"Curr Diabetes Rev"},{"issue":"2","key":"2026031804535524800_luag041-B29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/3\/luag041\/67386775\/luag041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/3\/luag041\/67386775\/luag041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:54:08Z","timestamp":1773824048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag041\/8527142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,23]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag041","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,23]]},"article-number":"luag041"}}